INZY – inozyme pharma, inc. (US:NASDAQ)
Stock Stats
News
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines [Yahoo! Finance]
Inozyme Pharma, Inc. (NASDAQ: INZY) is now covered by analysts at Raymond James. They set an "outperform" rating and a $26.00 price target on the stock.
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
Inozyme Pharma to Present at Upcoming Investor Conferences
Form SC 13G Inozyme Pharma, Inc. Filed by: Affinity Asset Advisors, LLC
Form SC 13G/A Inozyme Pharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC
Form SC 13G Inozyme Pharma, Inc. Filed by: BlackRock, Inc.
Form 10-Q Inozyme Pharma, Inc. For: Sep 30
Form 8-K Inozyme Pharma, Inc. For: Nov 05
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.